ArticleOncotarget2018
CD39
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 72 citations in OpenAlex.
- Trial
- Cancer associated fibroblast-T cell crosstalk promotes purinergic synthesis in non-small cell lung cancer (NSCLC).Oncoimmunology · 2026Article
- Mendelian randomization study explores the peripheral immunological characteristics of colorectal cancer.Discover oncology · 2025Article
- Mendelian randomization analysis of blood metabolites and immune cell mediators in relation to GVHD and relapse.BMC medicine · 2025Article
- The role of Treg cells in colorectal cancer and the immunotherapy targeting Treg cells.Frontiers in immunology · 2025Review
- CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.Cancer discovery · 2024Article
- In-depth immune profiling of peripheral blood mononuclear cells in patients with pancreatic ductal adenocarcinoma reveals discriminative immune subpopulations.Cancer science · 2024Article
- Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.Biology · 2024Review
- Immune checkpoints are predominantly co-expressed by clonally expanded CD4Journal of experimental & clinical cancer research : CR · 2023Article
- Location of CD39Journal for immunotherapy of cancer · 2023Article
- Review immune response of targeting CD39 in cancer.Biomarker research · 2023Review
- Overexpression of Potential Markers of Regulatory and Exhausted CD8International journal of molecular sciences · 2023Article
- The potential of regulatory T cell-based therapies for alopecia areata.Frontiers in immunology · 2023Review
- Liposomes loaded with vitamin D3 induce regulatory circuits in human dendritic cells.Frontiers in immunology · 2023Article
- Associations of different immune checkpoints-expressing CD4BMC cancer · 2022Article
- Proline metabolism reprogramming of trained macrophages induced by early respiratory infection combined with allergen sensitization contributes to development of allergic asthma in childhood of mice.Frontiers in immunology · 2022Article
- Study of PD-1 Customization and Autoimmune T Cells for Advanced Colorectal Cancer with High MSI Expression.Contrast media & molecular imaging · 2022Article
- Article
- Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations.BMC immunology · 2021Article
- CD39 Regulation and Functions in T Cells.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing knowledge of the function and regulation of tumor-infiltrating lymphocytes has led to new insights in cancer immunotherapy. Regulatory T cells (Treg) accumulate in colon tumors, and we recently showed that CD39
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.